AB0654 TOCILIZUMAB IS PROTECTIVE AGAINST SARS-COV2 INFECTION OR NOT?

Background: SARS-COV2 (Covid19) pandemic has a scaring burden on hospitals and health care providers all over the world. Unfortunately, after one year of pandemic, millions persons are infected either mild symptoms or critical ones unexplained deaths. Till now, No effective treatment vaccination. Researches showed that Covid 19 associated with elevated interleukin-6. Subsequently, Studies reported tocilizumab (IL-6 antagonist) may be in patients even though other were shown it is not reduction mortality. (1,2) Therefore question rheumatic diseases who already receiving having primary protection against infection comparing to biologicals conventional Therapy not. Objectives: Our objective was determine if tocolizumab had biologics. Methods: A Retrospective study done among 100 (Group 1: 10 tocilizumab, Group2: 40 (30 antiTNF IL17 antagonist), Group3: cDMARDs) from March Dec 2020. Detailed history, clinical presentation, laboratory, computed tomography chest PCR for covid presented patients. Results: Among median age 21, patient (19%) (2 6 antiTNF, 1 antagonist, cDMARDs). Symptoms fever (89.4%), Fatigue (78.9%), myalgia Headache (73.7%), Dyspnea (52.6%), Cough (47.3%), pain (26.3%) hypoxia (5%). CT findings positive (52.63%) while 15 out (78.94%). Nevertheless, there no significant statistically difference between groups according SARS-COV2. (p=0.704) Conclusion: Tocilizumab protective (COVID 19) compared biological cDMARDs diseases. References: [1]Tleyjeh IM, Kashour Z, Damlaj M, et al. Efficacy safety COVID-19 patients: living systematic review meta-analysis. Clinical Microbiology Infection. 2020 Nov 5. [2]Tsai, A., Diawara, O., Nahass, R.G. Impact administration mortality severe COVID-19. 2020; Sci Rep 10: 19131 Disclosure Interests: None declared.